Quality-of-life issues in head and neck cancer

Life Priorities in Head and Neck Cancer Patients Between Ages of 45 to 65

Diseases in head and neck cancer patients and applied therapies according to former affect life quality to a higher extent. In this paper, life priorities in 49 patients with head and neck cancer who referred to Gulhane Military Medical Academy for diagnostic and therapeutic purposes and the relationship between these priorities and sociodemographic properties have been studied. Following life priorities have been observed more important for the patients: to communicate with people in social places, to eat without any help by themselves, external appearance, taste and odor sense, continuing sexual life. Other priorities have been observed less important for the patients: attending social activities like cinema and theater, swimming pool and sea sports, money required for check-ups, necessities like time. Besides, these necessities do not show dissimilarities to any significant extent according to sociodemographic properties of the patients.

Quality of life for patients with hypopharyngeal cancer after different therapeutic modalities

BACKGROUND

Concurrent chemoradiation therapy (CCRT) and transoral laser microsurgery (TLM) have become therapeutic selections for organ preservation in patients with hypopharyngeal cancer.

METHODS

Our cross-sectional, observational study assesses quality of life (QOL) in patients with hypopharyngeal cancers receiving TLM plus radiotherapy (RT) compared with those treated with CCRT only or radical open surgery (nearly all of whom also received RT or CCRT). QOL was assessed at least 6 months posttreatment.

RESULTS

The study included 87 patients. Patients receiving open surgery reported significantly more sensory and speech disturbances than the others and more dental problems than the TLM group; the CCRT group experienced more xerostomia than the others, more weight loss, and dysphagia than the open surgery group; TLM patients experience fewer difficulties in emotional and social functioning, financial impact, and cough.

CONCLUSION

TLM may provide comparable, if not better, QOL for patients relative to the other therapeutic regimens for selective advanced cases of hypopharyngeal cancer.

Diagnosis of head-and-neck cancer from exhaled breath

Background:

Head-and-neck cancer (HNC) is the eighth most common malignancy worldwide. It is often diagnosed late due to a lack of screening methods and overall cure is achieved in <50% of patients. Head-and-neck cancer sufferers often develop a second primary tumour that can affect the entire aero-digestive tract, mostly HNC or lung cancer (LC), making lifelong follow-up necessary.

Methods:

Alveolar breath was collected from 87 volunteers (HNC and LC patients and healthy controls) in a cross-sectional clinical trial. The discriminative power of a tailor-made Nanoscale Artificial Nose (NA-NOSE) based on an array of five gold nanoparticle sensors was tested, using 62 breath samples. The NA-NOSE signals were analysed to detect statistically significant differences between the sub-populations using (i) principal component analysis with ANOVA and Student's t-test and (ii) support vector machines and cross-validation. The identification of NA-NOSE patterns was supported by comparative analysis of the chemical composition of the breath through gas chromatography in conjunction with mass spectrometry (GC–MS), using 40 breath samples.

Results:

The NA-NOSE could clearly distinguish between (i) HNC patients and healthy controls, (ii) LC patients and healthy controls, and (iii) HNC and LC patients. The GC–MS analysis showed statistically significant differences in the chemical composition of the breath of the three groups.

Conclusion:

The presented results could lead to the development of a cost-effective, fast, and reliable method for the differential diagnosis of HNC that is based on breath testing with an NA-NOSE, with a future potential as screening tool.

Effect of intraoral low-level laser therapy on quality of life of patients with head and neck cancer undergoing radiotherapy

BACKGROUND

Low-level laser therapy has been used to reduce complications of head and neck cancer treatment. The aim was to assess the impact of laser in the quality of life (QOL) of patients receiving radiotherapy.

METHODS

Sixty outpatients were randomly assigned into 2 groups. The laser group received applications and the placebo group received sham laser. QOL was assessed using the University of Washington QOL questionnaire. A repeated-measures analysis of variance (ANOVA) was used for comparisons of overall QOL scores and Mann-Whitney test compared changes in domain scores.

RESULTS

A decrease in QOL scores was observed in both groups and the reduction in the laser group was significantly lower (p < .01). Changes in QOL scores regarding pain, chewing, and saliva domains were evident in the placebo group. Both health-related QOL and overall QOL were rated higher by patients who received laser therapy.

CONCLUSION

Laser therapy reduces the impact of radiotherapy on the QOL of patients with head and neck cancer.

Recent new approaches to the treatment of head and neck cancer

Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer in the world and affects 50,000 Americans annually. During the past 20 years, treatments for HNSCC have changed dramatically due largely to the advent of novel approaches such as combined modality therapy, as well as improvements in surgical and radiotherapeutic techniques. Ongoing advances in the multidisciplinary management of this complex and multivariate disease process are resulting in improved function, quality of life and survival. Here, we review state-of-the-art therapy and presents selected advances in the treatment of head and neck cancer.

Rationale and clinical validation of epidermal growth factor receptor as a target in the treatment of head and neck cancer

Recurrent/metastatic head and neck cancer is an area of high, unmet treatment need. There is a strong rationale for targeting the epidermal growth factor receptor (EGFR) in head and neck cancer as most of these tumors express high levels of EGFR relative to normal tissue, with high expression correlating with poor patient outcome. This rationale has been validated in extensive preclinical studies. Two small molecules with EGFR inhibitory activity, gefitinib ('Iressa', ZD1839) and erlotinib ('Tarceva', OSI-774), and a humanized monoclonal antibody against the EGFR extracellular domain, cetuximab ('Erbitux', C225), are in clinical trials for advanced head and neck cancer. The initial results of these trials are promising. Gefitinib and erlotinib show activity as monotherapy in patients with recurrent or metastatic head and neck cancer, and have an acceptable safety profile compared with conventional chemotherapy. Gefitinib, which can be given at doses below the maximum tolerated dose, is associated with slightly lower rates of adverse events than erlotinib, which is dosed at the maximum tolerated dose. Combinations of cetuximab with radiotherapy or platinum-based chemotherapy have also shown activity in phase I/II studies. Both gefitinib and cetuximab have entered phase III studies. The results of these trials, which will mature over the next few years, will help determine the optimal use of EGFR agents in head and neck cancers.

Can we assess quality of life in patients with head and neck cancer? A preliminary report from the American Academy of Maxillofacial Prosthetics

Survival statistics alone may no longer be valid when used as evidence of effective outcomes. Patient satisfaction is an end point that needs further evaluation and should be included in the outcomes assessment. A 133-item questionnaire has been designed by a special committee of the American Academy of Maxillofacial Prosthetics (AAMP) to assess the quality of life of patients with head and neck cancer impacting the orofacial region. This survey will be distributed to the entire population of 7 geographically dispersed treatment centers in the United States for a 2-year period. Patients will be stratified into several subgroups, including radiation/nonradiation, maxillary/mandibular, and surgical reconstruction/prostheses. Separate analyses will be conducted for each subgroup, and comparisons will be made within subgroups to test the sensitivity of the questionnaire to a known difference. A revised version of the AAMP questionnaire, limited to 50 items of interest to patients, will be validated against 2 established head and neck cancer questionnaires. This article provides background on previous quality-of-life studies and reviews the need for and aims of the AAMP assessment instrument.